June 15, 2020 – The U.S. FDA has approved a new indication for Juvéderm® VolumaTM XC (hyaluronic acid),
manufactured by Allergan Aesthetics, for augmentation of the chin region
June 15, 2020 – The U.S. FDA has revoked its Emergency Use Authorization (EUA) for oral formulations of
chloroquine and hydroxychloroquine to be used as potential treatments for COVID-19
June 12, 2020 – The U.S. FDA has approved UpliznaTM (inebilizumab-cdon), manufactured by Viela Bio, to
treat neuromyelitis optica spectrum disorder (NMOSD) in adults who test positive
June 12, 2020 – The U.S. FDA has approved Tivicay® PD (dolutegravir) tablets for oral suspension,
manufactured by ViiV Healthcare, for use in combination with other
May 20, 2020 The U.S. FDA has approved a new indication for Lynparza® (olaparib), manufactured by
AstraZeneca and Merck, to treat adult patients who have deleterious or suspected deleterious germline
May 15, 2020 – The U.S. FDA has approved a new indication for Pomalyst® (pomalidomide), manufactured
by Bristol Myers Squibb. It is indicated to treat AIDS-related Kaposi sarcoma
May 15, 2020 – The U.S. FDA has approved QinlockTM (ripretinib), manufactured by Deciphera
Pharmaceuticals, to treat adult patients who have advanced gastrointestinal